SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549

                              Amendment No.1
                                   to
                              Schedule 13D

                Under the Securities Exchange Act of 1934
                                      
                                      
                              Endorex Corp.                
                            (Name of Issuer)
        

                     Common Stock, $0.001 par value
                     (Title of Class of Securities)
    
    
                              452916 40 6           
                            (CUSIP Number)

                                       
                          Dr. Gerald Vosika
                        3505 Riverview Circle
                      Moorhead, Minnesota 56560         
            (Name, Address and Telephone Number of Persons
            Authorized to Receive Notices and Communications)
    
    
    
                            July 31, 1996          
       (Date of Event which Requires Filing of this Statement)
    
    
    If the filing person has previously filed a statement on Schedule
    13G to report the acquisition which is the subject of this
    Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3)
    or (4), check the following box [ ].

    Check the following box if a fee is being paid with this
    statement [ ].
    
    CUSIP No.  
         
    1.  Name of Reporting Person              Gerald Vosika
        
        S.S. or I.R.S. Identifica-
        tion No. of Above Person              ###-##-####
    
    2.  Check the Appropriate        (a)
        Box if a Member of a Group   (b) X
    
    3.  SEC Use Only
    
    4.  Source of Funds               PF
    
    5.  Check if Disclosure of        Not Applicable
        Legal Proceedings is
        Required Pursuant to
        Items 2(d) or 2(e)
    
    6.  Citizenship or Place          United States
        of Organization
    
        Number of Shares              7. Sole Voting 
        Beneficially Owned               Power           2,143,499      
        by Each Reporting             8. Shared Voting
        Person With                      Power                 -0-     
    
                                      9. Sole Dispositive
                                         Power           2,143,499       
    
                                     10. Shared Dispositive
                                         Power                 -0-     
    
    
    11.  Aggregate Amount Beneficially
         Owned By Each Reporting 
         Person                                          2,143,499       
    
    12.  Check if the Aggregate Amount
         in Row (11) Excludes Certain
         Shares                                     Not Applicable      

    13.  Percent of Class Represented by
         Amount in Row (11)                
       
    14.  Type of Reporting Person                  IN

    Item 1.  Security and Issuer.
    
         The class of equity securities to which this Statement relates is
       shares of common stock, par value $0.001 per share (the "Shares"),
       of Endorex Corp. (formerlyImmunotherapeutics, Inc.), a Delaware
       corporation, (the "Company").  The principal executive offices of
       the Company are located at 3233 Fifteenth Street South, Fargo, North
       Dakota  58104.
    
    
    Item 2.  Identity and Background.
    
         This Statement is being filed by Gerald Vosika ("Vosika").  The
       residence address of Vosika is 3505 Riverview Circle, Moorhead,
       Minnesota 56560.  The present principal occupation of Vosika is
       Chairman of the Board of the Company.
    
         Vosika has not, during the last five years (i) been convicted in
       a criminal proceeding (excluding traffic violations or similar
       misdemeanors) or (ii) been a party to a civil proceeding of a
       judicial or administrative body of competent jurisdiction and as
       a result of such proceeding was or is subject to a judgment, decree
       or final order enjoining future violations of, or prohibiting or
       mandating activities subject to, federal or state securities laws or
       finding any violation with respect to such laws.
    
       Mr. Vosika is a United States citizen.
    
    Item 3.  Source and Amount of Funds or Other Consideration.
    
      On July 31, 1996, Vosika exercised options to purchase an aggregate
      of 2,100,000 shares of the Company's Common Stock.  Of the 2,100,000
      shares, 2,000,000 were purchased on exercise of a Stock Option
      Agreement dated March 21, 1996 at an exercise price of $.065 per share
      and 100,000 shares were purchased on exercise of an option dated
      January 19, 1996 at an exercise price of $0.07 per share.  Prior to
      exercise of the options Vosika held 43,499 shares and continues to
      hold options to purchase 175,000 shares at an exercise price of $0.07.
      The funds used to pay the exercise price were from Vosika's cash
      assets.
    
        Of the shares held by Vosika, 500,000 are the subject of a ten-year
      option granted to a non-affiliated person.  Such option is exerciseable
      at a price of $0.10 per share.

   Item 4.  Purpose of Transaction.
    
        The purpose of the acquisition of the shares was to increase Vosika's
      stock ownership in the Company.  The shares were purchased for
      investment.
    
        As of the date hereof, Vosika does not have any plans or proposals
      which relate to or would result in (a) the acquisition by any person of
      additional securities of the Company, or the disposition of securities
      of the Company;  (b) an extraordinary corporate transaction, such as a
      merger, reorganization or liquidation, involving the Company or any of
      its subsidiaries; (c) a sale or transfer of a material amount of assets
      of the Company or any of its subsidiaries; (d) any change in the present
      board of directors or management of the Company including any plans or
      proposals to change the number or term of directors or to fill any
      existing vacancies on the board; (e) any material change in the present
      capitalization or dividend policy of the Company; (f) any other material
      change in the Company's business or corporate structure; (g) changes in
      the Company's Certificate of Incorporation or other actions which may
      impede the acquisition of control of the Company by any person; (h)
      causing a class of securities of the Company to be delisted from a
      national securities exchange or to cease to be authorized to be quoted
      in an inter-dealer  quotation system of a registered national securities
      association; (i) a class of equity securities of the Company becoming
      eligible for termination of registration pursuant to Section 12(g)(4)
      of the Act; or (j) any action similar to any of those enumerated above.  

    Item 5.   Interest in Securities of the Issuer.
    
        As of December 20, 1996 Vosika holds beneficially the following
        securities of the Company.
    
                                            Shares of Common   Percentage of
                                            Stock issuable     shares of 
    Title of security          Amount       upon exercise      Common Stock(1)
    
    Common Stock              2,143,499          -0-               13.10%
    
    Option                      175,000          -0-                0.01$ 
    
                                                           TOTAL   13.11%

      (1) Calculated in accordance with Rule 13d-3.
    
    
    
    Item 6.  Contracts, Arrangements, Understandings or Relationships With
             Respect to Securities of the Issuer.
    
        Vosika is a party to the Option dated as of September 24, 1996 the
      terms and conditions of which are described above.
    
    
    Item 7.  Material to be Filed as Exhibits.
    
             Exhibit                                       Page
    
    
       Not applicable.
    
    
    
       SIGNATURE
    
    
        After reasonable inquiry and to the best of my knowledge and belief,
      the undersigned certifies that the information set forth in this
      statement is true, complete and correct.
    
    
    
    Dated:   January 29, 1997
                                            
        
                                    /s/ Gerald J. Vosika

                                    Gerald Vosika